Management of refractory angina: an update
Authors:
- 23 December 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (3) , 269-283
Abstract
Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacological approaches to treating refractory angina, including guideline directed drug combination and dosages. The symptomatic and prognostic impact of advanced and novel revascularization strategies such as chronic total occlusion PCI, transmyocardial laser revascularization, coronary sinus occlusion, radiation therapy for recurrent restenosis, and spinal cord stimulation are also covered and recommendations of the 2019 ESC Guidelines on the Diagnosis and Management of Chronic Coronary Syndromes discussed. Finally, the potential clinical use of current angiogenetic and stem cell therapies in reducing ischaemia and/or pain is evaluated.Keywords
This publication has 111 references indexed in Scilit:
- Long-term survival in patients with refractory anginaEuropean Heart Journal, 2013
- Anti-Anginal and Anti-Ischemic Effects of Late Sodium Current InhibitionCardiovascular Drugs and Therapy, 2012
- Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular eventsEuropean Heart Journal, 2011
- Nitric oxide synthases: regulation and functionEuropean Heart Journal, 2011
- Intramyocardial, Autologous CD34+ Cell Therapy for Refractory AnginaCirculation Research, 2011
- The Anti-Ischemic and Anti-Anginal Properties of StatinsCurrent Atherosclerosis Reports, 2010
- Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early AtherosclerosisCirculation, 2010
- VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN TrialMolecular Therapy, 2009
- Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defectsAmerican Heart Journal, 2006
- Transmyocardial Revascularization with a Carbon Dioxide Laser in Patients with End-Stage Coronary Artery DiseaseNew England Journal of Medicine, 1999